News Merck, Pfizer and Gilead all interested in Medivation buy-ou... Sanofi has competition in its bid to acquire cancer specialist
News Zepatier to add competition to Europe’s hep C market Will company pursue same aggressive pricing strategy in Europe?
Views & Analysis Many millions still untreated – but hep C boom is already ov... Gilead has led a revolution in curing hepatitis C, but now faces a slowdown.
News German pricing changes to hit blockbuster revenues But pharma will be able to negotiate confidential prices.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
